On August 9, 2024, in the culturally rich city of Xuzhou, we celebrated the grand opening of the Xuzhou Zhongshu Donghu Research Site, a new facility established by Xuzhou Zhongshu Biotechnology Co., Ltd., a subsidiary of ICE Bioscience. This marks a significant expansion of our capabilities in drug discovery and development, particularly in the CNS field. Simultaneously, the CNS Drug Innovation Forum was held, bringing together leading figures from the pharmaceutical industry to explore the latest trends and emerging opportunities in CNS drug innovation.
Time and Location:
Date: August 9, 2024
Venue: Primus Hotel Xuzhou Dalong Lake
About Xuzhou Zhongshu Biotechnology Co., Ltd.
Xuzhou Zhongshu Biotechnology Co., Ltd., a subsidiary of ICE Bioscience, specializes in preclinical drug screening and efficacy evaluation. The recent establishment of the Xuzhou Zhongshu Donghu Research Site enhances our ability to serve pharmaceutical enterprises and research institutions globally. We adhere to a customer-first philosophy, leading with technology, prioritizing research, and ensuring quality. Through innovation and dedicated service, Xuzhou Zhongshu accelerates drug development and enhances the clinical translation of potential therapies.
With a core technical team that possesses extensive experience and a deep understanding of both domestic and international drug screening and evaluation, Xuzhou Zhongshu provides personalized solutions tailored to clients' needs. The new Donghu Research Site features a high-standard facility equipped with SPF-grade animal rooms, professional research laboratories, and state-of-the-art equipments. This infrastructure supports targeted research in drug development, forming a comprehensive, systematic, and stable drug evaluation service system.
Introduction to Xuzhou Zhongshu Biotechnology Platform
Comprehensive In Vivo Pharmacodynamic Evaluation Platform: We have established animal models for a wide range of diseases, including neurodegenerative diseases, psychiatric disorders, traumatic brain and spinal cord injuries, cardiovascular diseases, pain and sensory disorders, cancers, and metabolic diseases. Our platform also covers models for conditions such as pulmonary fibrosis, dry eye syndrome, liver injury, and osteoporosis.
Professional In Vitro Pharmacodynamic Evaluation Platform: Utilizing advanced drug induction and transgenic technologies, we have developed stable cell lines and primary neuron cultures related to various disease models. We also offer a comprehensive pathology analysis platform.
Our services encompass all aspects of preclinical pharmacological research and pharmacodynamic evaluations, aligning with the standards required for IND applications. Our core products and services, which offer significant advantages, are primarily focused on the central nervous system (CNS). These services are divided into four key segments:
Neurodegenerative Diseases: We focus on conditions such as Parkinson’s disease (PD), Alzheimer’s disease (AD), multiple system atrophy (MSA), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), and neuromyelitis optica (NMO).
Psychiatric Disorders: Our research models address conditions such as depression, schizophrenia, anxiety, post-traumatic stress disorder (PTSD), hallucinations, and addiction.
Cerebral and Spinal Cord Injuries: Our focus includes stroke models due to cerebral ischemia and hemorrhage, spinal cord injury (SCI), traumatic brain injury (TBI), and thrombosis models.
Pain: We offer comprehensive model development for a broad range of mainstream pain models.
We look forward to Xuzhou Zhongshu Biotechnology Co., Ltd., with its new Donghu Research Site, making significant contributions to drug discovery in the CNS field in the future!
